CoChat
Sign Up
Cited by 13Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

The incubation period of Alzheimer’s disease and the timing of tau versus amyloid misfolding and spreading within the brain

Open access
Goudsmit, Jaap·2016·European Journal of Epidemiology
DOI 10.1007/s10654-016-0144-8PMC PMC4819914
Open this paper in CoChat — free accountOpen PDF

Abstract

Having spent most of my career studying viral infections and their clinical manifestations, in particular AIDS, I have developed a keen interest in the incubation of diseases. In recent years I have focused my attention on Alzheimer’s disease (AD), so for me the key question concerning this illness is: when does AD start to develop? AD is tentatively diagnosed on the basis of a set of clinical symptoms (progressive irreversible decline in memory and other cognitive functions) and confirmed by neuropathology (brain atrophy accompanied by the accumulation of abundant extracellular amyloid β plaques and intraneuronal neurofibrillary tau lesions) [1] (Fig. 1a).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s10654-016-0144-8

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The study used MEPS data, which only follow a patient for at most 2 years, which may not be long enough for dementia to occur and may underestimate the risk of dementia.

    “First, we used MEPS data, which only follow a patient for at most 2 years, which may not be long enough for dementia to occur and underestimate the risk of dementia [38].”

    From Association between first-line antidepressant use and risk of dementia in older adults: a retrospective cohort study (2023) · cites this paper as [38]

    The paper’s Fig. 1 caption describes a preclinical Alzheimer’s disease period that might last 17 years, supporting the concern that two years may be too short to observe clinical onset. It does not discuss MEPS or show that a two-year follow-up underestimates dementia risk; that is the citing authors’ inference. (LLM, conf=0.83)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 35

  1. Goedert M. Neurodegeneration. Alzheimer’s and Parkinson’s diseases: the prion concept in relation to assembled Abeta, tau, and alpha-synuclein. Science. 2015;349(6248):1255555. · DOI
  2. Goudsmit J, Morrow CH, Asher DM, et al. Evidence for and against the transmissibility of Alzheimer disease. Neurology. 1980;30(9):945–50. · DOI
  3. de Wolf F, Goudsmit J, Paul DA, et al. Risk of AIDS related complex and AIDS in homosexual men with persistent HIV antigenaemia. Br Med J (Clin Res Ed). 1987;295(6598):569–72. · DOI
  4. de Wolf F, Lange JM, Houweling JT, et al. Appearance of predictors of disease progression in relation to the development of AIDS. AIDS. 1989;3(9):563–9. · DOI
  5. Goudsmit J, de Wolf F, Paul DA, et al. Expression of human immunodeficiency virus antigen (HIV-Ag) in serum and cerebrospinal fluid during acute and chronic infection. Lancet. 1986;2(8500):177–80. · DOI
  6. Goudsmit J, Lange JM, Paul DA, Dawson GJ. Antigenemia and antibody titers to core and envelope antigens in AIDS, AIDS-related complex, and subclinical human immunodeficiency virus infection. J Infect Dis. 1987;155(3):558–60. · DOI
  7. Goudsmit J, Wolters EC, Bakker M, et al. Intrathecal synthesis of antibodies to HTLV-III in patients without AIDS or AIDS related complex. Br Med J (Clin Res Ed). 1986;292(6530):1231–4. · DOI
  8. Lange J, Goudsmit J. Decline of antibody reactivity to HIV core protein secondary to increased production of HIV antigen. Lancet. 1987;1(8530):448. · DOI
  9. Lange JM, Coutinho RA, Krone WJ, et al. Distinct IgG recognition patterns during progression of subclinical and clinical infection with lymphadenopathy associated virus/human T lymphotropic virus. Br Med J (Clin Res Ed). 1986;292(6515):228–30. · DOI
  10. Lange JM, Paul DA, Huisman HG, et al. Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS. Br Med J (Clin Res Ed). 1986;293(6560):1459–62. · DOI
  11. Goudsmit J, Epstein LG, Paul DA, et al. Intra-blood-brain barrier synthesis of human immunodeficiency virus antigen and antibody in humans and chimpanzees. Proc Natl Acad Sci USA. 1987;84(11):3876–80. · DOI
  12. Belsky DW, Caspi A, Houts R, et al. Quantification of biological aging in young adults. Proc Natl Acad Sci USA. 2015;112(30):E4104–10. · DOI · Paper page
  13. Klemera P, Doubal S. A new approach to the concept and computation of biological age. Mech Ageing Dev. 2006;127(3):240–8. · DOI
  14. Levine ME. Modeling the rate of senescence: can estimated biological age predict mortality more accurately than chronological age? J Gerontol A Biol Sci Med Sci. 2013;68(6):667–74. · DOI
  15. Horvath S. DNA methylation age of human tissues and cell types. Genome Biol. 2013;14(10):R115. · DOI · Paper page
  16. Horvath S, Zhang Y, Langfelder P, et al. Aging effects on DNA methylation modules in human brain and blood tissue. Genome Biol. 2012;13(10):R97. · DOI
  17. Zetterberg H, Wilson D, Andreasson U, et al. Plasma tau levels in Alzheimer’s disease. Alzheimers Res Ther. 2013;5(2):9. · DOI
  18. Wang T, Xiao S, Liu Y, et al. The efficacy of plasma biomarkers in early diagnosis of Alzheimer’s disease. Int J Geriatr Psychiatry. 2014;29(7):713–9. · DOI
  19. Ingelson M, Blomberg M, Benedikz E, et al. Tau immunoreactivity detected in human plasma, but no obvious increase in dementia. Dement Geriatr Cogn Disord. 1999;10(6):442–5. · DOI
  20. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306–19. · DOI · Paper page
  21. Chien DT, Szardenings AK, Bahri S, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. J Alzheimers Dis. 2014;38(1):171–84. · DOI
  22. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112(4):389–404. · DOI · Paper page
  23. Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011;70(11):960–9. · DOI · Paper page
  24. Mercken M, Vandermeeren M, Lubke U, et al. Monoclonal antibodies with selective specificity for Alzheimer Tau are directed against phosphatase-sensitive epitopes. Acta Neuropathol. 1992;84(3):265–72. · DOI
  25. Kim KS, Miller DL, Sapienza VJ, Chen CJ, Bai C, Grunke-Iqbal I, Currie JR, Wisniewski HM. Production and characterization of monoclonal antibodies reactive to synthetic cerebrovascular amyloid peptide. Neurosci Res Commun. 1988;2:121–30.
  26. Hatami A, Monjazeb S, Glabe C. The anti-amyloid-beta monoclonal antibody 4G8 recognizes a generic sequence-independent epitope associated with alpha-Synuclein and Islet amyloid polypeptide amyloid fibrils. J Alzheimers Dis. 2015;50(2):517–25. · DOI
  27. Tenreiro S, Eckermann K, Outeiro TF. Protein phosphorylation in neurodegeneration: friend or foe? Front Mol Neurosci. 2014;7:42. · DOI · Paper page
  28. Duyckaerts C, Braak H, Brion JP, et al. PART is part of Alzheimer disease. Acta Neuropathol. 2015;129(5):749–56. · DOI
  29. Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357–67. · DOI · Paper page
  30. Jack CR Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207–16. · DOI · Paper page
  31. Braak H, Del Tredici K. The preclinical phase of the pathological process underlying sporadic Alzheimer’s disease. Brain. 2015;138(Pt 10):2814–33. · DOI · Paper page
  32. Itzhaki RF. Herpes simplex virus type 1 and Alzheimer’s disease: increasing evidence for a major role of the virus. Front Aging Neurosci. 2014;6:202. · DOI
  33. de Wolf F, Spijkerman I, Schellekens PT, et al. AIDS prognosis based on HIV-1 RNA, CD4+ T-cell count and function: markers with reciprocal predictive value over time after seroconversion. AIDS. 1997;11(15):1799–806. · DOI
  34. Musiek ES, Holtzman DM. Three dimensions of the amyloid hypothesis: time, space and ‘wingmen’. Nat Neurosci. 2015;18(6):800–6. · DOI · Paper page
  35. Thal DR, Rub U, Schultz C, et al. Sequence of Abeta-protein deposition in the human medial temporal lobe. J Neuropathol Exp Neurol. 2000;59(8):733–48. · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Goudsmit, J.
Affiliations
Amsterdam UMC Location University of Amsterdam (NL)
Corresponding author
Goudsmit, Jaap
Venue
European Journal of Epidemiology
Publisher
Springer Science and Business Media LLC
Published
2016-02
Volume
31
Issue
2
Pages
99-105
ISSN
  • 0393-2990 (ISSN-L)
  • 1573-7284
DOI
10.1007/s10654-016-0144-8
PMC
PMC4819914
OpenAlex
W2310641279
Cited by
13
References
5
Citations by year
2025: 1 · 2024: 1 · 2023: 3 · 2021: 1 · 2020: 1 · 2019: 1 · 2018: 1 · 2017: 2 · 2016: 2
FWCI
0.81
Type
journal article
Language
en
Open access
Licence
Locations
  • European Journal of Epidemiology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Pure Amsterdam UMC (submittedVersion, other-oa)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Alzheimer's disease, incubation period, tau misfolding, protein misfolding, neurofibrillary tangles, amyloid plaques, disease onset, neuropathology
MeSH terms
Aging, Alzheimer Disease, Brain, Humans, Time Factors, Amyloid beta-Peptides, Plaque, Amyloid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review